Carlos A Vaz Fragoso1,2, Gail McAvay2, Peter H Van Ness2, Richard Casaburi3, Robert L Jensen4, Neil MacIntyre5, H Klar Yaggi1,2, Thomas M Gill2, John Concato1,2. 1. 1 Veterans Affairs Clinical Epidemiology Research Center, West Haven, Connecticut. 2. 2 Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut. 3. 3 Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, California. 4. 4 LDS Hospital and University of Utah, Salt Lake City, Utah; and. 5. 5 Division of Pulmonary and Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina.
Abstract
RATIONALE: The Global Lung Initiative (GLI) provides age-appropriate criteria for establishing spirometric impairment, including mild, moderate, and severe chronic obstructive pulmonary disease (COPD) and restrictive pattern, but its association with respiratory-related phenotypes has not been evaluated. OBJECTIVES: To evaluate respiratory-related phenotypes in GLI-defined spirometric impairment. METHODS: In COPDGene (N = 10,131 patients; age range, 45-81 yr; average smoking history, 44.3 pack-years), we evaluated spirometry, dyspnea (modified Medical Research Council grade, ≥2), poor respiratory health-related quality of life (St. George's Respiratory Questionnaire total score, ≥25), poor exercise performance (6-minute-walk distance, <391 m), bronchodilator reversibility (FEV1 change, >12% and ≥200 ml), and computed tomography-diagnosed emphysema and gas trapping (>5% and >15% of lung, respectively). MEASUREMENTS AND MAIN RESULTS: GLI established normal spirometry in 5,100 patients (50.3%), mild COPD in 669 (6.6%), moderate COPD in 865 (8.5%), severe COPD in 2,522 (24.9%), and restrictive pattern in 975 (9.6%). Relative to normal spirometry, graded associations with respiratory-related phenotypes were found for mild, moderate, and severe COPD, with respective adjusted odds ratios (95% confidence intervals) as follows: dyspnea-1.31 (1.10-1.56), 2.20 (1.81-2.68), and 10.73 (8.04-14.33); poor respiratory health-related quality of life-1.49 (1.28-1.75), 2.69 (2.08-3.47), and 14.61 (10.09-21.17); poor exercise performance-1.11 (0.94-1.31), 1.58 (1.33-1.88), and 4.58 (3.42-6.12); bronchodilator reversibility-2.76 (2.24-3.40), 5.18 (4.29-6.27), and 6.21 (5.06-7.62); emphysema-4.86 (3.16-7.47), 6.41 (4.09-10.05), and 17.79 (10.79-29.32); and gas trapping-3.92 (3.12-4.93), 5.20 (3.82-7.07), and 16.28 (9.71-27.30). Restrictive pattern was also associated with multiple respiratory-related phenotypes at a level similar to moderate COPD, but it was otherwise not associated with emphysema (0.89 [0.60-1.32]) or gas trapping (1.15 [0.92-1.42]). CONCLUSIONS: GLI-defined spirometric impairment establishes clinically meaningful respiratory disease, as validated by graded associations with respiratory-related phenotypes.
RATIONALE: The Global Lung Initiative (GLI) provides age-appropriate criteria for establishing spirometric impairment, including mild, moderate, and severe chronic obstructive pulmonary disease (COPD) and restrictive pattern, but its association with respiratory-related phenotypes has not been evaluated. OBJECTIVES: To evaluate respiratory-related phenotypes in GLI-defined spirometric impairment. METHODS: In COPDGene (N = 10,131 patients; age range, 45-81 yr; average smoking history, 44.3 pack-years), we evaluated spirometry, dyspnea (modified Medical Research Council grade, ≥2), poor respiratory health-related quality of life (St. George's Respiratory Questionnaire total score, ≥25), poor exercise performance (6-minute-walk distance, <391 m), bronchodilator reversibility (FEV1 change, >12% and ≥200 ml), and computed tomography-diagnosed emphysema and gas trapping (>5% and >15% of lung, respectively). MEASUREMENTS AND MAIN RESULTS:GLI established normal spirometry in 5,100 patients (50.3%), mild COPD in 669 (6.6%), moderate COPD in 865 (8.5%), severe COPD in 2,522 (24.9%), and restrictive pattern in 975 (9.6%). Relative to normal spirometry, graded associations with respiratory-related phenotypes were found for mild, moderate, and severe COPD, with respective adjusted odds ratios (95% confidence intervals) as follows: dyspnea-1.31 (1.10-1.56), 2.20 (1.81-2.68), and 10.73 (8.04-14.33); poor respiratory health-related quality of life-1.49 (1.28-1.75), 2.69 (2.08-3.47), and 14.61 (10.09-21.17); poor exercise performance-1.11 (0.94-1.31), 1.58 (1.33-1.88), and 4.58 (3.42-6.12); bronchodilator reversibility-2.76 (2.24-3.40), 5.18 (4.29-6.27), and 6.21 (5.06-7.62); emphysema-4.86 (3.16-7.47), 6.41 (4.09-10.05), and 17.79 (10.79-29.32); and gas trapping-3.92 (3.12-4.93), 5.20 (3.82-7.07), and 16.28 (9.71-27.30). Restrictive pattern was also associated with multiple respiratory-related phenotypes at a level similar to moderate COPD, but it was otherwise not associated with emphysema (0.89 [0.60-1.32]) or gas trapping (1.15 [0.92-1.42]). CONCLUSIONS:GLI-defined spirometric impairment establishes clinically meaningful respiratory disease, as validated by graded associations with respiratory-related phenotypes.
Authors: Sanja Stanojevic; Angie Wade; Janet Stocks; John Hankinson; Allan L Coates; Huiqi Pan; Mark Rosenthal; Mary Corey; Patrick Lebecque; Tim J Cole Journal: Am J Respir Crit Care Med Date: 2007-11-15 Impact factor: 21.405
Authors: Elizabeth A Regan; John E Hokanson; James R Murphy; Barry Make; David A Lynch; Terri H Beaty; Douglas Curran-Everett; Edwin K Silverman; James D Crapo Journal: COPD Date: 2010-02 Impact factor: 2.409
Authors: Carlos A Vaz Fragoso; Gail McAvay; Peter H Van Ness; Richard Casaburi; Robert L Jensen; Neil MacIntyre; Thomas M Gill; H Klar Yaggi; John Concato Journal: Am J Respir Crit Care Med Date: 2015-10-01 Impact factor: 21.405
Authors: C G Cote; C Casanova; J M Marín; M V Lopez; V Pinto-Plata; M M de Oca; L J Dordelly; H Nekach; B R Celli Journal: Eur Respir J Date: 2007-11-07 Impact factor: 16.671
Authors: William W Stringer; Janos Porszasz; Surya P Bhatt; Meredith C McCormack; Barry J Make; Richard Casaburi Journal: Chronic Obstr Pulm Dis Date: 2019-07-24
Authors: Carlos A Vaz Fragoso; Hilary C Cain; Richard Casaburi; Patty J Lee; Lynne Iannone; Linda S Leo-Summers; Peter H Van Ness Journal: Respir Care Date: 2017-07-11 Impact factor: 2.258
Authors: Pamela L Lutsey; Nemin Chen; Maria C Mirabelli; Kamakshi Lakshminarayan; David S Knopman; Keith A Vossel; Rebecca F Gottesman; Thomas H Mosley; Alvaro Alonso Journal: Am J Respir Crit Care Med Date: 2019-06-01 Impact factor: 21.405
Authors: Y Kubota; S J London; M Cushman; A M Chamberlain; W D Rosamond; S R Heckbert; N Zakai; A R Folsom Journal: J Thromb Haemost Date: 2016-11-08 Impact factor: 5.824